PCVX earnings analysis
What we found in PCVX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Vaxcyte reported a substantial net loss of $320.6 million for Q1 2026, significantly widening from a loss of $140.7 million in Q1 2025, highlighting continued pressure on expenses particularly in R&D. Revenue remains non-existent, with the company relying heavily on cash reserves of $2.7 billion to fund ongoing operations amid an aggressive expansion in clinical trials for its vaccine candidates.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Net Loss
- Net loss for the quarter was $320.6 million, up 127.8% from $140.7 million in Q1 2025.
- R&D Expenses Surge
- Research and development expenses reached $312.8 million, a 111.1% increase from $148.1 million in Q1 2025.
- High Cash Reserve
- Ending cash balance was $2.7 billion, sufficient to fund operational needs for at least 12 months.
- No Revenue Generated
- Despite vigorous R&D efforts, no revenue was reported as the company remains in the clinical stage.
- Increased Clinical Trial Activity
- Clinical trial related expenses increased by $45 million due to the commencement of multiple Phase 3 studies.
- Continuing Need for Capital
- The company indicated it will need to raise substantial capital for ongoing development and commercialization efforts.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Cash Burn Risk
- Net cash used in operating activities for Q1 2026 was $280.6 million, necessitating future capital raises.
- Regulatory and Development Uncertainties
- Ongoing clinical trials face risks of delays or failures, impacting future revenue potential.
- Intellectual Property Vulnerabilities
- Potential challenges in obtaining or maintaining patent protection for vaccine candidates.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-2.3
What they said about what is next.
Company has not offered forward numeric guidance.
The filing reads worse than the one before it.
What came before.
- 10-K · February 24, 2026
- Vaxcyte positions itself as a cell-free protein synthesis vaccine developer focused on a broad-spectrum pneumococcal conjugate vaccine (PCV) franchise and other bacterial targets, leveraging its XpressCF™ platform. The…
- 10-Q · November 4, 2025
- Vaxcyte reported a wider quarterly loss: net loss of $(212,830) and GAAP EPS of $(1.56) for the three months ended September 30, 2025, compared with net loss $(103,124) and EPS $(0.83) in the year-ago quarter. Operating…
- 10-Q · August 6, 2025
- Vaxcyte reported a Q2 net loss of $166,573 (three months ended June 30, 2025) and GAAP diluted EPS of $(1.22), wider than prior-year Q2 EPS of $(1.10). Operating expenses rose materially (total operating expense…
- 10-K · February 25, 2025
- Vaxcyte is a clinical-stage vaccine company with meaningful clinical progress: VAX-31 showed positive Phase 1/2 immunogenicity in 1,015 adults and received FDA breakthrough therapy designation in November 2024, and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PCVX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever